- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01159665
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) (MIVI-10)
An Open-Label, Ascending-Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects Scheduled for Primary Pars Plana Vitrectomy
Study Overview
Detailed Description
Open-label, ascending-exposure-time, single center trial in which a total of 36 subjects will be enrolled. The time to remove the vitreous will be recorded and a vitreous sample will be obtained at the beginning of vitrectomy for determination of ocriplasmin activity; 32 subjects will receive 125 μg ocriplasmin intravitreal injection prior to vitrectomy and 4 subjects will not receive ocriplasmin intravitreal injection prior to vitrectomy (control arm).
Study drug will be administered in the mid-vitreous by injection. The study eye will be examined after study drug injection to exclude retinal non-perfusion or other complications.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, B-3000
- University Hospital Leuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects aged ≥ 18
- Eye disease for which a primary vitrectomy is indicated
- Best Corrected Visual Acuity (BCVA) of 20/800 or better in the non-study eye
- Written informed consent obtained from the subject prior to inclusion in the trial
Exclusion Criteria:
- Proliferative diabetic retinopathy.
- Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either Optical Coherence Tomography (OCT) and/or fluorescein angiogram in the study eye
- Aphakia in the study eye
- High myopia (more than 8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length >28 mm is an exclusion).
- Subjects with history of rhegmatogenous retinal detachment in the either eye
- Subjects who have had ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior three months
- Subjects who have had laser photocoagulation to the macula in the study eye at any time
- Subjects with uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 26 mm Hg in spite of treatment with anti-glaucoma medication)
- Subjects with a history of uveitis in either eye.
- Subjects who are pregnant or of child-bearing potential not utilizing an acceptable form of contraception. Acceptable methods of birth control include intrauterine device, oral, implanted, or injected contraceptives, and barrier methods with spermicide.
- Subjects who, in the Investigators view, will not complete all visits and investigations
- Subjects who have participated in an investigational drug trial within the past 30 days
- Subjects who have previously participated in this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PPV 5-30 minutes after injection
Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
|
125µg ocriplasmin intravitreal injection
Other Names:
|
Experimental: PPV 31-60 minutes after injection
Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
|
125µg ocriplasmin intravitreal injection
Other Names:
|
Experimental: PPV 2-4 hours after injection
Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
|
125µg ocriplasmin intravitreal injection
Other Names:
|
Experimental: PPV 24 hours (+2 hours) after injection
Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
|
125µg ocriplasmin intravitreal injection
Other Names:
|
Experimental: PPV 7 days (+1 day) after injection
Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
|
125µg ocriplasmin intravitreal injection
Other Names:
|
No Intervention: PPV without injection
Control Arm, no ocriplasmin intravitreal injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocriplasmin Activity Levels in Vitreous Samples Obtained at the Beginning of Vitrectomy.
Time Frame: 5-30 minutes, 31-60 minutes, 2-4 hours, 1 day, or 7 days after ocriplasmin injection
|
Vitreous samples were obtained at the beginning of vitrectomy in subjects at various times relative to ocriplasmin injection (post-injection), for the determination of ocriplasmin activity (Group 1 [5-30 minutes]; Group 2 [31-60 minutes]; Group 3 [2-4 hours]; Group 4 [24 hours ±2 hours]; Group 5 [7 days ±1 day].
Subjects in Group 6 (control) did not receive the ocriplasmin injection.
|
5-30 minutes, 31-60 minutes, 2-4 hours, 1 day, or 7 days after ocriplasmin injection
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time Necessary to Remove the Vitreous From the Eye
Time Frame: From first start of vitrectomy cutter till the end of core vitrectomy phase
|
PPV was performed in all subjects.
The time necessary to remove the vitreous from the eye, measured from first start of vitrectomy cutter till end of core vitrectomy phase, was calculated.
|
From first start of vitrectomy cutter till the end of core vitrectomy phase
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TG-MV-010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitrectomy
-
VISTA OphthalmicsCBCC Global ResearchActive, not recruitingVitrectomyUnited States
-
ThromboGenicsCompletedVitrectomyUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Innovative MedicalCompletedVitrectomyUnited States
-
Vanderbilt University Medical CenterAlcon ResearchCompleted
-
Alcon ResearchCompleted
-
Universitaire Ziekenhuizen KU LeuvenTerminated
-
AllerganCompletedVitrectomyUnited States, Czech Republic
-
Kocaeli UniversityCompleted
-
Eyegate Pharmaceuticals, Inc.Completed
Clinical Trials on ocriplasmin
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenCompleted
-
ThromboGenicsCompletedSymptomatic Vitreomacular AdhesionUnited States, Belgium
-
ThromboGenicsCompleted
-
ThromboGenicsCompletedVitreomacular Adhesion Including Macular HoleUnited States
-
ThromboGenicsCompletedExudative Age-Related Macular Degeneration | Focal Vitreomacular AdhesionUnited States, United Kingdom, Germany, France, Belgium, Italy
-
Alcon ResearchCompletedSymptomatic Vitreomacular AdhesionJapan
-
ThromboGenicsTerminatedDisease Progression | Diabetic Retinopathy | Posterior Vitreous DetachmentUnited States, Czechia, United Kingdom, France, Germany, Hungary, Spain, Israel, Italy
-
ThromboGenicsCompletedVitrectomyUnited States
-
Alcon ResearchCompletedVitreomacular Traction | Vitreomacular Adhesion
-
Alcon ResearchCompletedVitreomacular Traction | Vitreomacular AdhesionAustralia